Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
NCT06657274

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Led by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Updated on 2025-05-02

60

Participants Needed

3

Research Sites

89 weeks

Total Duration

On this page

Sponsors

I

IRCCS Centro San Giovanni di Dio Fatebenefratelli

Lead Sponsor

E

European Union - NextGenerationEU - PNRR M6C2 - Mission M6 - Component C2 - Investment 2.1 - Valorizzazione e potenziamento della ricerca biomedica del SSN

Collaborating Sponsor

AI-Summary

What this Trial Is About

The increase in life expectancy in recent decades has led to a large number of people living into old age and an increased risk of developing Chronic Neurological Diseases (CNDs) such as neurodegenerative diseases. A higher cumulative risk of dementia has been largely demonstrated in Mild Cognitive Impairment (MCI) and Subjective Cognitive Complaints (SCCs) subjects and in Parkinson's Disease (PD) patients, as compared to the general population. These disorders result in an impairment of the individual's abilities to perform daily tasks. As their disease progresses, patients become dependent on medical services and on family support. Given the limited effectiveness of pharmacological treatments, non-pharmacological interventions to prevent and treat cognitive deficits and the associated difficulties with activities of daily living in neurodegenerative disease patients have gained attention in recent years and, among these, cognitive training offers a potential approach for dementia prevention and improvement of cognitive function. A critical aspect of cognitive training programs is that the most promising interventions have involved intensive in-person sessions that are unlikely to be cost-effective or feasible for large-scale implementation. Within the framework of non-pharmacological interventions, the use of technology to assist the person at risk and/or with mild dementia at home and to extend rehabilitation services in the treatment of dementia has gradually gained importance. Telerehabilitation technologies allow to provide services remotely in patients' homes, allowing access to health care to patients living in rural settings or with mobility difficulties. In addition, the telerehabilitation modality offers the advantage of providing rehabilitation within the natural environment of the patient's home, making the treatment more realistic and possibly more generalizable to the person's daily life. The present project proposes to test a home-based asynchronous cognitive telerehabilitation program aimed at enhancing the continuum of care for MCI, SCCs and PD, using technology. The proposed study is a single blind randomized controlled trial (RCT) involving subjects with CNDs randomly assigned to one out of two intervention groups: i) the tele@cognitive group, who will receive at-home cognitive telerehabilitation (tele@cognitive treatment); ii) the Active Control Group (ACG), who will receive at-home unstructured cognitive stimulation. The aim of the project will be threefold: \[1\] to test the short-term and long-term efficacy of tele@cognitive protocol as compared to an unstructured cognitive at-home rehabilitation in the treatment of a cohort of patients with CNDs; \[2\] to explore the changes induced by tele@cognitive intervention on biomolecular and neurophysiological markers; \[3\] to explore potential cognitive, neurobiological and neurophysiological predictors of response to tele@cognitive treatment.

CONDITIONS

Official Title

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Parkinson's Disease with Hoehn & Yahr stage less than 3, Mild Cognitive Impairment (CDR scale 30.5, MMSE 24), or Subjective Cognitive Complaints
  • Montreal Cognitive Assessment (MoCA) corrected score 5.36
  • At least 5 years of education
  • Age between 18 and 85 years
  • Native Italian speaker
  • No marked hearing or visual impairments; normal or corrected-to-normal vision
  • Signed informed consent to participate
  • Availability of a caregiver or study partner to support the participant
  • No rehabilitation program ongoing or in the last 3 months before enrollment
  • Stable drug treatment for the last 3 months, if any
Not Eligible

You will not qualify if you...

  • Any medical or psychiatric illness that could interfere with completing assessments
  • Any medical condition that contraindicates Transcranial Magnetic Stimulation (TMS)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli

Brescia, IT, Italy, 25125

Actively Recruiting

2

IRCCS Centro Neurolesi Bonino Pulejo

Messina, IT, Italy, 98124

Actively Recruiting

3

Fondazione Don Carlo Gnocchi - ONLUS, Milan

Milan, IT, Italy, 20148

Actively Recruiting

Loading map...

Research Team

M

Maria Cotelli, PhD

CONTACT

R

Rosa Manenti, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here